

Medidata AI Supports PPD's \$60M Study Award in Rare Oncology Indication

PPD, Thermo Fisher's clinical research business, partnered with Medidata AI Intelligent Trials to leverage broad industry performance data to more accurately forecast patient enrollment rates. This enabled PPD to reduce the projected clinical trial timeline and be awarded a key study.

KEY TAKEAWAYS



RESULTS

PPD was awarded a \$60M Phase III trial using a data-driven approach and ability to forecast more accurate patient enrollment rates. This opportunity helped PPD increase revenue and gain an edge in the increasingly competitive CRO landscape. Medidata AI's patient enrollment and data quality metrics were foundational to PPD forecasting enrollment rates aligned with the specific patient population.

